Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03597295 · OUTCOME

Progression-free Survival (PFS)

A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202) · Source last updated 2025-08-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
up to 16.8 months

What was measured

According to RECIST 1.1, PFS was defined as the length of time from the initial infusion of study drug until the earliest date of disease progression, as determined by ICR, or death due to any cause, if occurring sooner than progression.

Analysis population: Full Analysis Set. Median PFS time was estimated using the Kaplan-Meier method. The confidence interval for median PFS time was calculated using the method of Brookmeyer and Crowley.

Groups in this outcome

Retifanlimab 500 mg

Participants received retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Retifanlimab 500 mg94

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Retifanlimab 500 mg2.3Not reported1.93.6Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.9
        upper Limit
        3.6
        value
        2.3
denoms
  1. counts
    1. group Id
      OG000
      value
      94
    units
    Participants
description
According to RECIST 1.1, PFS was defined as the length of time from the initial infusion of study drug until the earliest date of disease progression, as determined by ICR, or death due to any cause, if occurring sooner than progression.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants received retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).
    id
    OG000
    title
    Retifanlimab 500 mg
param Type
MEDIAN
population Description
Full Analysis Set. Median PFS time was estimated using the Kaplan-Meier method. The confidence interval for median PFS time was calculated using the method of Brookmeyer and Crowley.
reporting Status
POSTED
time Frame
up to 16.8 months
title
Progression-free Survival (PFS)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice